The use of intraoral devices in reducing oral and dental side effects in head and neck cancer patients undergoing radiotherapy – a systematic review.

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

Download Full-text

Factors associated with depression over time in head and neck cancer patients: A systematic review

Psycho-Oncology ◽

10.1002/pon.5058 ◽

2019 ◽

Vol 28 (6) ◽

pp. 1159-1183 ◽

Cited By ~ 6

Author(s):

Laura H.A. Korsten ◽

Femke Jansen ◽

Ben J.F. Haan ◽

Danielle Sent ◽

Pim Cuijpers ◽

...

Keyword(s):

Systematic Review ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Factors Associated ◽

Over Time

Download Full-text

Nanoparticle-Based Chemotherapy Formulations for Head and Neck Cancer: A Systematic Review and Perspectives

Nanomaterials ◽

10.3390/nano10101938 ◽

2020 ◽

Vol 10 (10) ◽

pp. 1938

Author(s):

Jefferson Muniz de Lima ◽

Paulo Rogerio Bonan ◽

Danyel Elias da Cruz Perez ◽

Michael Hier ◽

Moulay A. Alaoui-Jamali ◽

...

Keyword(s):

Systematic Review ◽

Head And Neck Cancer ◽

Side Effects ◽

Head And Neck ◽

Neck Cancer ◽

Meta Analysis ◽

Basic Research ◽

Cochrane Central Register ◽

Level Of Evidence ◽

Mortality And Morbidity

Head and neck cancer (HNC) is a complex and heterogeneous disease associated with high mortality and morbidity worldwide. Standard therapeutic management of advanced HNC, which is based on radiotherapy often combined with chemotherapy, has been hampered by severe long-term side effects. To overcome these side effects, tumor-selective nanoparticles have been exploited as a potential drug delivery system to improve HNC therapy. A combination of MEDLINE, EMBASE, Cochrane Oral Health Group’s Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov from inception up to June 2020 was used for this systematic review. A total of 1747 published manuscripts were reviewed and nine relevant references were retrieved for analysis, while eight of them were eligible for meta-analysis. Based on these studies, the level of evidence about the efficacy of nanoformulation for HNC therapy on tumor response and adverse side effects (SAE) was low. Even though basic research studies have revealed a greater promise of nanomaterial to improve the outcome of cancer therapy, none of them were translated into clinical benefits for HNC patients. This systematic review summarized and discussed the recent progress in the development of targeted nanoparticle approaches for HNC management, and open-up new avenues for future perspectives.

Download Full-text